Epigenetic modifications of prostate-derived Ets transcription factor in breast cancer cells

Sabherwal,Yamini; Mahajan,Nitin; Zhang,Ming

doi:10.3892/or.2013.2661

Epigenetic modifications of prostate-derived Ets transcription factor in breast cancer cells

Authors:
- Yamini Sabherwal
- Nitin Mahajan
- Ming Zhang
View Affiliations

Affiliations: Department of Molecular Pharmacology and Biological Chemistry, Northwestern University, Chicago, IL 60611, USA
Published online on: August 6, 2013 https://doi.org/10.3892/or.2013.2661
Pages: 1985-1988

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The importance of epigenetic alterations such as DNA methylation, histone modification and nucleosome remodeling in breast cancer is well established. Epigenetic alterations are reversible, and much research has been focused on understanding these alterations with the aim of developing effective therapies. Prostate-derived Ets factor (PDEF) is a member of the Ets family of transcription factors and has long been under investigation for its key role in tumor development and progression. To date, no studies have been conducted to elucidate the epigenetic modifications of PDEF in cancer progression. Using breast and prostate cancer cells, we investigated the effect of the methylation inhibitor 5' azacytidine (AZA) on the expression of PDEF in these cells. The inhibition of methylation observed was specific to breast cancer cells as experiments with prostate cells did not exhibit any significant change. Notably, the expression of p21, a cyclin-dependent kinase (CDK) inhibitor 1 and also a target gene of PDEF, was found to be positively correlated with PDEF expression following 5'AZA treatment. Inhibition of methylation led to a decrease in the proliferation rate of MDA-MB-468 cells as revealed by MTT proliferation assay. Other epigenetic alterations such as histone modifications were not observed in these breast cancer cells following treatment with specific HDAC inhibitors. Our data suggest the possibility of epigenetic modification of PDEF due to DNA methylation and involvement of the cell cycle inhibitor p21. Future studies on the epigenetic alterations of PDEF in correlation with p21 or other targets may facilitate the development of effective therapies for the treatment of breast cancer.

View Figures

View References

1	Lustberg MB and Ramaswamy B: Epigenetic therapy in breast cancer. Curr Breast Cancer Rep. 3:34–43. 2011. View Article : Google Scholar : PubMed/NCBI
2	Yang X, Yan L and Davidson NE: DNA methylation in breast cancer. Endocr Relat Cancer. 8:115–127. 2001. View Article : Google Scholar
3	Connolly R and Stearns V: Epigenetics as a therapeutic target in breast cancer. J Mammary Gland Biol Neoplasia. 17:191–204. 2012. View Article : Google Scholar : PubMed/NCBI
4	Locke WJ and Clark SJ: Epigenome remodelling in breast cancer: insights from an early in vitro model of carcinogenesis. Breast Cancer Res. 14:2152012. View Article : Google Scholar : PubMed/NCBI
5	Siegel R, DeSantis C, Virgo K, et al: Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 62:220–241. 2012. View Article : Google Scholar : PubMed/NCBI
6	Oikawa T: ETS transcription factors: possible targets for cancer therapy. Cancer Sci. 95:626–633. 2004. View Article : Google Scholar : PubMed/NCBI
7	Galang CK, Muller WJ, Foos G, Oshima RG and Hauser CA: Changes in the expression of many Ets family transcription factors and of potential target genes in normal mammary tissue and tumors. J Biol Chem. 279:11281–11292. 2004. View Article : Google Scholar : PubMed/NCBI
8	Hsu T, Trojanowska M and Watson DK: Ets proteins in biological control and cancer. J Cell Biochem. 91:896–903. 2004. View Article : Google Scholar : PubMed/NCBI
9	Li R, Pei H and Watson DK: Regulation of Ets function by protein - protein interactions. Oncogene. 19:6514–6523. 2000. View Article : Google Scholar : PubMed/NCBI
10	Seth A and Watson DK: ETS transcription factors and their emerging roles in human cancer. Eur J Cancer. 41:2462–2478. 2005. View Article : Google Scholar : PubMed/NCBI
11	Ghadersohi A and Sood AK: Prostate epithelium-derived Ets transcription factor mRNA is overexpressed in human breast tumors and is a candidate breast tumor marker and a breast tumor antigen. Clin Cancer Res. 7:2731–2738. 2001.PubMed/NCBI
12	Sood AK, Saxena R, Groth J, et al: Expression characteristics of prostate-derived Ets factor support a role in breast and prostate cancer progression. Hum Pathol. 38:1628–1638. 2007. View Article : Google Scholar : PubMed/NCBI
13	Yamada N, Tamai Y, Miyamoto H and Nozaki M: Cloning and expression of the mouse Pse gene encoding a novel Ets family member. Gene. 241:267–274. 2000.
14	Ghadersohi A, Odunsi K, Lele S, et al: Prostate derived Ets transcription factor shows better tumor-association than other cancer-associated molecules. Oncol Rep. 11:453–458. 2004.
15	Schaefer JS, Sabherwal Y, Shi HY, et al: Transcriptional regulation of p21/CIP1 cell cycle inhibitor by PDEF controls cell proliferation and mammary tumor progression. J Biol Chem. 285:11258–11269. 2010. View Article : Google Scholar : PubMed/NCBI
16	Sabherwal Y, Mahajan N, Helseth DL, Gassmann M, Shi H and Zhang M: PDEF downregulates stathmin expression in prostate cancer. Int J Oncol. 40:1889–1899. 2012.PubMed/NCBI
17	Ghoshal K and Bai S: DNA methyltransferases as targets for cancer therapy. Drugs Today. 43:395–422. 2007. View Article : Google Scholar : PubMed/NCBI
18	Acharya MR, Sparreboom A, Venitz J and Figg WD: Rational development of histone deacetylase inhibitors as anticancer agents: a review. Mol Pharmacol. 68:917–932. 2005. View Article : Google Scholar : PubMed/NCBI
19	Matsuzaki Y, Sowa Y, Hirose T, Yokota T and Sakai T: Histone deacetylase inhibitors: promising agents for ‘gene-regulating chemoprevention’ and ‘molecular-targeting prevention’ of cancer. Environ Health Prev Med. 8:157–160. 2003.
20	Ropero S and Esteller M: The role of histone deacetylases (HDACs) in human cancer. Mol Oncol. 1:19–25. 2007. View Article : Google Scholar : PubMed/NCBI
21	Braiteh F, Soriano AO, Garcia-Manero G, et al: Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. Clin Cancer Res. 14:6296–6301. 2008. View Article : Google Scholar : PubMed/NCBI
22	Karahoca M and Momparler RL: Pharmacokinetic and pharmacodynamic analysis of 5-aza-2′-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy. Clin Epigenetics. 5:32013.
23	Feldman RJ, Sementchenko VI, Gayed M, Fraig MM and Watson DK: Pdef expression in human breast cancer is correlated with invasive potential and altered gene expression. Cancer Res. 63:4626–4631. 2003.
24	Ghadersohi A, Pan D, Fayazi Z, Hicks DG, Winston JS and Li F: Prostate-derived Ets transcription factor (PDEF) downregulates survivin expression and inhibits breast cancer cell growth in vitro and xenograft tumor formation in vivo. Breast Cancer Res Treat. 102:19–30. 2007. View Article : Google Scholar : PubMed/NCBI
25	Oettgen P, Finger E, Sun Z, et al: PDEF, a novel prostate epithelium-specific Ets transcription factor, interacts with the androgen receptor and activates prostate-specific antigen gene expression. J Biol Chem. 275:1216–1225. 2000. View Article : Google Scholar
26	Thompson HG, Harris JW, Wold BJ, Lin F and Brody JP: p62 overexpression in breast tumors and regulation by prostate-derived Ets factor in breast cancer cells. Oncogene. 22:2322–2333. 2003. View Article : Google Scholar : PubMed/NCBI
27	Zhang M, Maass N, Magit D and Sager R: Transactivation through Ets and Ap1 transcription sites determines the expression of the tumor-suppressing gene maspin. Cell Growth Differ. 8:179–186. 1997.PubMed/NCBI
28	Zhang M, Magit D and Sager R: Expression of maspin in prostate cells is regulated by a positive Ets element and a negative hormonal responsive element site recognized by androgen receptor. Proc Natl Acad Sci USA. 94:5673–5678. 1997. View Article : Google Scholar : PubMed/NCBI
29	Gros C, Fahy J, Halby L, et al: DNA methylation inhibitors in cancer: recent and future approaches. Biochimie. 94:2280–2296. 2012. View Article : Google Scholar : PubMed/NCBI
30	Marks PW: Decitabine for acute myeloid leukemia. Expert Rev Anticancer Ther. 12:299–305. 2012. View Article : Google Scholar : PubMed/NCBI
31	Nebbioso A, Carafa V, Benedetti R and Altucci L: Trials with ‘epigenetic’ drugs: an update. Mol Oncol. 6:657–682. 2012.